(Q33571873)

28 July 2017

1 reference

title

Outcomes assessment of drug treatment in multiple sclerosis clinical trials (English)

1 reference

28 July 2017

0 references

Malone M

1

1 reference

28 July 2017

Lomaestro B

series ordinal

2

1 reference

28 July 2017

publication date

1 March 1996

1 reference

28 July 2017

1 reference

28 July 2017

volume

9

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

198-210

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199609030-00003

28 July 2017

exact match

0 references

cites work

Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials.

1 reference

12 December 2020

Measuring health-related quality of life

1 reference

12 December 2020

Immunotherapy in multiple sclerosis, Part 1.

1 reference

12 December 2020

Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

1 reference

12 December 2020

Immunotherapy in multiple sclerosis, Part 2.

1 reference

12 December 2020

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

12 December 2020

Therapy for multiple sclerosis.

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group

1 reference

12 December 2020

Use of alternative health therapies by people with multiple sclerosis: an exploratory study.

1 reference

12 December 2020

The current status of studies of aminopyridines in patients with multiple sclerosis

1 reference

12 December 2020

Update on multiple sclerosis therapy.

1 reference

12 December 2020

4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis therapy. A practical guide.

1 reference

12 December 2020

On the possible viral aetiology of multiple sclerosis.

1 reference

12 December 2020

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

1 reference

12 December 2020

Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?

1 reference

12 December 2020

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

12 December 2020

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

12 December 2020

Does interferon beta cause initial exacerbation of multiple sclerosis?

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Cyclosporine and multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Clinical scoring methods for multiple sclerosis

1 reference

12 December 2020

PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS

1 reference

12 December 2020

Treatment of spasticity with tizanidine in multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

1 reference

12 December 2020

4-Aminopyridine improves clinical signs in multiple sclerosis

1 reference

12 December 2020

The psychosocial aspects of multiple sclerosis.

1 reference

12 December 2020

Intrathecal baclofen for spasticity of spinal origin: seven years of experience

1 reference

12 December 2020

Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis

1 reference

12 December 2020

An antispasticity effect of threonine in multiple sclerosis

1 reference

12 December 2020

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

1 reference

12 December 2020

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Dantrolene sodium and hepatic injury

1 reference

12 December 2020

Immunoglobulins promote remyelination in the central nervous system

1 reference

12 December 2020

Symptomatic therapy of multiple sclerosis.

1 reference

12 December 2020

Treatment of spasticity with botulinum toxin: a double-blind study

1 reference

12 December 2020

Intrathecal baclofen in severe spasticity

1 reference

12 December 2020

Botulinum toxin A for spasticity, muscle spasms, and rigidity

1 reference

12 December 2020

Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study

1 reference

12 December 2020

A critical appraisal of the quality of quality-of-life measurements

1 reference

12 December 2020

Immunotherapy for multiple sclerosis

1 reference

12 December 2020

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

12 December 2020

A placebo-controlled trial of isoprinosine in patients with multiple sclerosis

1 reference

12 December 2020

A brain MRI study of different types of chronic-progressive multiple sclerosis

1 reference

12 December 2020

10.2165/00019053-199609030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1011962803

0 references

1 reference